Concepts (100)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Typhoid Fever | 7 | 2021 | 195 | 3.030 |
Why?
|
| Salmonella typhi | 6 | 2021 | 199 | 2.460 |
Why?
|
| Drug Resistance, Bacterial | 6 | 2024 | 1058 | 1.570 |
Why?
|
| Paratyphoid Fever | 4 | 2021 | 34 | 1.560 |
Why?
|
| Typhoid-Paratyphoid Vaccines | 4 | 2021 | 39 | 1.540 |
Why?
|
| Mass Vaccination | 2 | 2018 | 109 | 1.110 |
Why?
|
| Viral Vaccines | 2 | 2022 | 596 | 0.980 |
Why?
|
| Fluoroquinolones | 3 | 2020 | 308 | 0.860 |
Why?
|
| Salmonella paratyphi A | 3 | 2021 | 47 | 0.830 |
Why?
|
| Pneumonia, Staphylococcal | 1 | 2022 | 40 | 0.820 |
Why?
|
| India | 10 | 2024 | 2349 | 0.610 |
Why?
|
| Methicillin-Resistant Staphylococcus aureus | 1 | 2022 | 699 | 0.520 |
Why?
|
| Staphylococcal Infections | 1 | 2022 | 1409 | 0.440 |
Why?
|
| Truth Disclosure | 1 | 2016 | 434 | 0.400 |
Why?
|
| Travel | 1 | 2018 | 796 | 0.390 |
Why?
|
| Influenza, Human | 1 | 2022 | 1521 | 0.380 |
Why?
|
| Anti-Infective Agents | 1 | 2018 | 984 | 0.360 |
Why?
|
| Anti-Bacterial Agents | 6 | 2024 | 7439 | 0.350 |
Why?
|
| Models, Theoretical | 1 | 2020 | 3577 | 0.310 |
Why?
|
| Ciprofloxacin | 2 | 2019 | 312 | 0.270 |
Why?
|
| Pandemics | 3 | 2022 | 8635 | 0.250 |
Why?
|
| Telemedicine | 1 | 2022 | 3041 | 0.240 |
Why?
|
| Streptococcal Vaccines | 1 | 2024 | 44 | 0.230 |
Why?
|
| Developing Countries | 1 | 2016 | 2887 | 0.220 |
Why?
|
| Microbial Sensitivity Tests | 2 | 2020 | 1956 | 0.210 |
Why?
|
| Methicillin | 1 | 2022 | 62 | 0.210 |
Why?
|
| Streptococcus agalactiae | 1 | 2024 | 337 | 0.200 |
Why?
|
| Meningitis, Bacterial | 1 | 2024 | 221 | 0.200 |
Why?
|
| Chemotactic Factors | 1 | 2022 | 197 | 0.200 |
Why?
|
| Virulence Factors | 1 | 2024 | 513 | 0.180 |
Why?
|
| Streptococcal Infections | 1 | 2024 | 616 | 0.170 |
Why?
|
| Intensive Care Units | 2 | 2024 | 3744 | 0.170 |
Why?
|
| Spinal Dysraphism | 1 | 2021 | 174 | 0.160 |
Why?
|
| Antibodies, Viral | 2 | 2022 | 3155 | 0.160 |
Why?
|
| Africa | 2 | 2021 | 710 | 0.160 |
Why?
|
| Nepal | 1 | 2018 | 305 | 0.140 |
Why?
|
| Rickettsiaceae Infections | 1 | 2016 | 2 | 0.140 |
Why?
|
| Dengue Virus | 1 | 2019 | 201 | 0.140 |
Why?
|
| Cross Reactions | 1 | 2018 | 818 | 0.140 |
Why?
|
| Vaccines, Conjugate | 1 | 2018 | 328 | 0.130 |
Why?
|
| Clinical Trials, Phase II as Topic | 1 | 2018 | 628 | 0.130 |
Why?
|
| Dengue | 1 | 2019 | 254 | 0.130 |
Why?
|
| Asia | 1 | 2017 | 618 | 0.130 |
Why?
|
| Genotype | 3 | 2019 | 12982 | 0.130 |
Why?
|
| Genes, Bacterial | 1 | 2018 | 1079 | 0.120 |
Why?
|
| Immunization Programs | 1 | 2017 | 268 | 0.120 |
Why?
|
| Humans | 24 | 2024 | 761326 | 0.120 |
Why?
|
| Staphylococcus aureus | 1 | 2022 | 1459 | 0.120 |
Why?
|
| Intensive Care Units, Neonatal | 1 | 2021 | 844 | 0.110 |
Why?
|
| Interferon-gamma | 1 | 2022 | 3159 | 0.110 |
Why?
|
| Infant | 7 | 2024 | 36202 | 0.110 |
Why?
|
| Child | 8 | 2022 | 80156 | 0.110 |
Why?
|
| Prenatal Care | 1 | 2021 | 1139 | 0.110 |
Why?
|
| Counseling | 1 | 2021 | 1546 | 0.110 |
Why?
|
| Disease Transmission, Infectious | 1 | 2018 | 559 | 0.110 |
Why?
|
| Antibodies, Neutralizing | 1 | 2022 | 1943 | 0.100 |
Why?
|
| Communicable Disease Control | 1 | 2018 | 849 | 0.100 |
Why?
|
| Vaccination | 2 | 2021 | 3381 | 0.100 |
Why?
|
| Prevalence | 3 | 2017 | 15719 | 0.090 |
Why?
|
| Patient Compliance | 1 | 2021 | 2690 | 0.090 |
Why?
|
| HIV Infections | 1 | 2016 | 17346 | 0.080 |
Why?
|
| Critical Care | 1 | 2022 | 2697 | 0.080 |
Why?
|
| Child, Preschool | 4 | 2019 | 42251 | 0.070 |
Why?
|
| Patient Discharge | 1 | 2021 | 3438 | 0.070 |
Why?
|
| RNA, Messenger | 1 | 2022 | 12787 | 0.070 |
Why?
|
| Cost of Illness | 1 | 2017 | 1935 | 0.070 |
Why?
|
| Sepsis | 1 | 2021 | 2587 | 0.070 |
Why?
|
| Adolescent | 5 | 2019 | 88305 | 0.070 |
Why?
|
| Infant Mortality | 2 | 2021 | 759 | 0.070 |
Why?
|
| Infant, Newborn | 5 | 2024 | 26211 | 0.060 |
Why?
|
| Gentamicins | 1 | 2024 | 251 | 0.050 |
Why?
|
| Research Design | 1 | 2018 | 6178 | 0.050 |
Why?
|
| Female | 9 | 2024 | 392485 | 0.050 |
Why?
|
| Calibration | 1 | 2024 | 818 | 0.050 |
Why?
|
| Oxygen Inhalation Therapy | 1 | 2024 | 410 | 0.050 |
Why?
|
| Phenotype | 1 | 2018 | 16603 | 0.040 |
Why?
|
| Age Factors | 1 | 2017 | 18401 | 0.040 |
Why?
|
| Pakistan | 1 | 2021 | 293 | 0.040 |
Why?
|
| Genome, Bacterial | 1 | 2024 | 785 | 0.040 |
Why?
|
| China | 1 | 2024 | 2348 | 0.040 |
Why?
|
| Male | 7 | 2024 | 360621 | 0.040 |
Why?
|
| Time Factors | 1 | 2018 | 39974 | 0.030 |
Why?
|
| Immunization | 1 | 2021 | 1226 | 0.030 |
Why?
|
| ROC Curve | 1 | 2024 | 3572 | 0.030 |
Why?
|
| Retinal Vasculitis | 1 | 2016 | 46 | 0.030 |
Why?
|
| Respiratory Insufficiency | 1 | 2024 | 1230 | 0.030 |
Why?
|
| Young Adult | 1 | 2020 | 59196 | 0.030 |
Why?
|
| Epidemics | 1 | 2019 | 511 | 0.030 |
Why?
|
| Diagnostic Tests, Routine | 1 | 2018 | 787 | 0.030 |
Why?
|
| Adult | 3 | 2024 | 221122 | 0.030 |
Why?
|
| Aged | 2 | 2024 | 169179 | 0.020 |
Why?
|
| Demography | 1 | 2016 | 1648 | 0.020 |
Why?
|
| Phylogeny | 1 | 2019 | 2809 | 0.020 |
Why?
|
| Middle Aged | 2 | 2024 | 220774 | 0.020 |
Why?
|
| Premature Birth | 1 | 2021 | 1782 | 0.020 |
Why?
|
| Randomized Controlled Trials as Topic | 1 | 2024 | 10203 | 0.020 |
Why?
|
| Animals | 1 | 2018 | 168388 | 0.020 |
Why?
|
| Retrospective Studies | 2 | 2024 | 80575 | 0.010 |
Why?
|
| Pregnancy | 1 | 2021 | 29858 | 0.010 |
Why?
|
| Treatment Outcome | 1 | 2024 | 64645 | 0.010 |
Why?
|
Concepts
(100)
Derived automatically from this person's publications.
Explore
_
Co-Authors
(9)
People in Profiles who have published with this person.
Explore
_
Similar People
(60)
People who share similar concepts with this person.
Explore
_
Same Department
People in same department with this person.
Explore
_